ClinicalTrials.gg
CompletedNCT02055703Updated Nov 3, 2015

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

A Phase 1 interventional study of E2609 and itraconazole in Healthy Subjects, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-11-03.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will be a single-center, open-label, drug-drug interaction study in healthy male and female subjects. The study will consist of 3 parts: A, B, and C. In Part A, the effect of itraconazole or rifampin on the pharmacokinetics (PK) of E2609 and metabolites will be assessed. Approximately 32 subjects will be assigned to 1 of 2 treatment groups (itraconazole or rifampin) in equal numbers, with approximately 16 subjects per group. In Part B, the effects of steady-state dosing of E2609 on the PK of digoxin will be assessed in approximately 18 subjects. In Part C, the effects of donepezil administered in combination with, or 2 hours after, E2609 dosing on the PK of E2609 and metabolites, will be assessed in approximately 24 subjects.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Healthy Subjects
03

In context

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female subjects aged 18-55 years inclusive at the time of
  2. Provide written informed consent
  3. Willing and able to comply with all aspects of the protocol

Exclusion criteria

Exclusion Criteria

  1. Any history of seizures or epilepsy (not including a history of simple febrile seizures in childhood) or disturbance of consciousness likely to be due to seizures
  2. A prolonged /QTc interval (QTc greater than 450 ms) as demonstrated by the mean of triplicate (ECGs), recorded at least 1 min apart, at Screening or Baseline Periods
  3. Evidence of disease (eg, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system) that in the opinion of the investigator(s) could affect the subject's safety or interfere with the study assessments or subjects who have a congenital abnormality in metabolism within 4 weeks before dosing.
  4. Any laboratory abnormalities considered clinically significant by the investigator, which may require further investigations or treatment
  5. Clinically significant illness which required medical treatment within 8 weeks or a clinically significant infection within 4 weeks of dosing
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
195 participants (actual)

Study arms

  • Experimental
    E2609

    Experimental drug for Parts A, B, and C

    Drug: itraconazole · Drug: rifampin · Drug: digoxin · Drug: donepezil

  • Active comparator
    itraconazole

    Comparator drug for Part A1

    Drug: E2609

  • Active comparator
    rifampin

    Comparator drug for Part A2

    Drug: E2609

  • Active comparator
    digoxin

    Comparator drug for Part B

    Drug: E2609

  • Active comparator
    donepezil

    Comparator drug for Part C

    Drug: E2609

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the pharmacokinetics (PK) of single oral doses of E2609 and metabolites in subjects dosed alone or in combination with either rifampin or itraconazole

    Primary PK Parameters being measured: AUC(0-t), AUC(0-inf), Cmax, tmax.

    Time frame: Up to 48 days (Part A)

  2. To evaluate the PK of single oral doses of digoxin in subjects dosed alone or in combination with E2609

    Primary PK Parameters being measured: AUC(0-t), AUC(0-inf), Cmax, tmax.

    Time frame: Up to 48 days (Part B)

  3. To evaluate the PK of single oral doses of E2609 and metabolites in subjects dosed alone, in combination with donepezil, or 2 hours before donepezil dosing

    Primary PK Parameters being measured: AUC(0-t), AUC(0-inf), Cmax, tmax.

    Time frame: Up to 86 day (Part C)

Secondary outcomes

  1. Safety and tolerability of single oral doses of E2609 in subjects in the presence and absence of rifampin, itraconazole, digoxin, or donepezil

    Safety assessments include monitoring and recording all adverse events (AEs), regular measurement of vital signs, and the performance of physical examinations.

    Time frame: Up to 182 days

  2. To evaluate the effects of DNA sequence variants potentially involved in absorption, distribution and metabolism of E2609.

    DNA samples will be collected, stored, and may be used to examine the role of genetic variability in other genes potentially involved in absorption, distribution, metabolism, and excretion.

    Time frame: Up to 182 days

07

Study locations

1 site
  • WCT Early Development
    San Antonio, Texas 78217, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Apr 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2014
First posted
Feb 5, 2014
Start
Jan 2014
Primary completionActual
Apr 2014
CompletionActual
May 2014
Last update
Nov 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02055703
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Feb 5, 2014
Start date
Jan 2014
Primary completion
Apr 2014
Completion
May 2014
Last update
Nov 3, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elenbecestat · Itraconazole · Rifampin · Digoxin · Donepezil

Start the discussion